Ocumetics Technology Announces Amendment to Brokered LIFE Offering Led by Centurion One Capital

Core Viewpoint - Ocumetics Technology Corp. has amended the terms of its previously announced brokered private placement, aiming to raise up to $2.5 million through the issuance of units at an amended price of $0.60 per unit [1][2]. Group 1: Offering Details - The amended offering will consist of up to 4,166,666 units, each unit comprising one common share and one common share purchase warrant, with the warrant allowing the purchase of a share at $0.75 for three years [2]. - The Lead Agent has been granted an option to sell an additional 625,000 units at the same price, potentially raising an extra $375,000 [3]. - The offering is expected to close around December 29, 2025, subject to necessary approvals [7]. Group 2: Use of Proceeds - The gross proceeds from the offering are intended to fund the Corporation's first-in-human clinical trials, ongoing research and development, and general corporate purposes [4]. Group 3: Regulatory and Compliance - The units will be offered through a private placement under specific exemptions in Canada and the United States, with no prospectus filing required in certain jurisdictions [5]. - Participation by insiders in the offering will be considered a related party transaction but is expected to be exempt from formal valuation and minority shareholder approval requirements [8]. Group 4: Company Overview - Ocumetics Technology Corp. is focused on developing advanced vision correction solutions, including innovative intraocular lenses designed to eliminate the need for corrective lenses [10][11].